Cancer: Targeted Agents for Use with Chemo-Radiotherapy

Deadline
Multiple
OPPORTUNITY NO.
PAR-16-111
MECHANISM
U01
RESEARCH AREA(S)
SYNOPSIS

Cooperative Agreement to Develop Targeted Agents for Use with Systemic Agents Plus Radiotherapy:

The purpose of this Funding Opportunity Announcement (FOA) is to invite cooperative agreement (U01) applications that propose studies to enhance pre-clinical in vitro and in vivo testing of NCI-prioritized molecularly targeted anti-cancer agents for use with radiation therapy combined with systemic chemotherapy. These studies should generate validated high-quality preclinical data on the effects of molecular therapeutics when added to standard-of-care therapies for solid tumors.

The specific purpose is to provide a more rational basis for prioritizing those NCI-supported investigational new drugs or agents (INDs) most likely to have clinical activity with chemo-radiotherapy. The overall goal is to accelerate the pace at which combined modality treatments with greater efficacy are identified and incorporated into standard practices for treatments of patients with solid tumors.

Deadlines:
• Pre-Application Submission Deadline: 45 days before application submission due date
• Application Submission Deadline: 5:00 PM local time of applicant organization, Dec. 14, 2016; July 14, 2017; Dec.14, 2017

 

ELIGIBILITY

Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.